Intergroup Phase III Study Reports Overall Survival Benefit with Revlimid® As Continuous Therapy for Patients with Multiple Myeloma

Celgene International Sàrl CELG announced that updated data from a National Cancer Institute-sponsored clinical study were presented by representatives of a network of researchers led by the Cancer and Leukemia Group B at the 2011 International Myeloma Workshop in Paris, France.